The Significance of the Cardiac Peptide NT-proBNP in the Assessment of Risk for Myocardial Revascularization in Patients with Decreased Left Ventricular Ejection Fraction
https://doi.org/10.15360/1813-9779-2010-2-38
Abstract
Objective: to substantiate a procedure for predicting the severity of postperfusion acute heart failure (AHF) from the baseline level of NT-proBNP during myocardial revascularization in patients with a left ventricular ejection fraction (LVEF) of less than 35%. Subjects and materials. Fifty-six patients with a LVEF of less than 35% were examined. A total of 3.5±0.1 (range 2—4) coronary arteries were shunted under cardio-pulmonary bypass (CPB) (71.0±5.5 min). The concentration of NT-proBNP was measured before surgery (Cardiac Reader®, Roche). Mortality rates, sympathomimetic agents’ dosages required after EC, and the frequency of use of intraaortic balloon pumping (IABP) were analyzed. Results. A good clinical course was observed in 47 cases (Group 1). AHF was recorded in 9 patients (Group 2). Comparative analysis demonstrated that the preoperative concentration of NT-proBNP (871±111 pg/ml in Group 1 and 1946±236 pg/ml in Group 2) was of the highest prognostic value as compared with the traditional indicators (p=0.0015). Patients with a NT-proBNP concentration of less than 600 pg/ml did not virtually need inotropic therapy after EC. In a group with a biomarker level of 600—1200 mg/ml, the infusion of dopamine and dobutamine achieved the traditional cardiotonic dosages and every three patients needed epinephrine. With NT-proBNP of 1200-2000 pg/ml, mortality from AHF was 15.4%; a need for epinephrine and IABC was 46.4 and 7.7%, respectively. The peptide concentration of more than 2000 pg/ml indicated the extremely high risk of severe AHF. In the postperfusion period, each patient was given epinephrine and an IABC system was installed in half of them. In this group mortality achieved 50%. Conclusion. It is expedient to determine a preoperative NT-proBNP concentration in a LVEF of less than 35% to predict AHF to be occurred after myocardial revascularization. The concentration of less than 1200 pg/ml may be considered to be a safe level of the peptide. Its content increase more than 2000 pg/ml suggests that there is an extremely high risk of severe AHF. The level of this biomarker may be a guide to choose an anesthetic tactic. Key words: NT-proBNP, cardiosurgery, heart failure.
About the Authors
V. V. MorozYu. V. Nikiforov
L. A. Krichevsky
V. M. Aseyev
O. G. Guseva
M. G. Burzhunova
V. Yu. Rybakov
References
1. Januzzi J. L., Camargo C. A., Anwaruddin S. et al.The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am. J. Cardiol. 2005; 95 (8): 948—954.
2. Riezebos R. K, RonnerE, TijssenJ. G., Laarman G.J.NT-ProBNP serum levels reflect severity and extent of ischemia in patients admitted with non-ST-elevation acute coronary syndrome. Acute Card. Care 2006; 8 (1): 51—57.
3. Андреев Д. А.Натрийуретические пептиды В-типа при сердечной недостаточности: диагностика, оценка прогноза и эффективности лечения. Лаб. медицина 2003; 6: 42—46.
4. Bettencourt P., Frioes F., Azevedo A. et al.Prognostic information provided by serial measurements of brain natriuretic peptide in heart failure. Int. J. Cardiol. 2004; 93 (1): 45—48.
5. Сапрыгин Д. Б., Мошина В. А.Клиническое значение определения мозгового натрийуретического пептида (аминотерминального фрагмента) — NT-proBNP, при кардиоваскулярной патологии. Лаб. медицина 2003; 8: 1—8.
6. Козлов И. А., Харламова И. Е.Натрийуретические пептиды: биохимия, физиология, клиническое значение. Общая реаниматология 2009; VI (1): 89—9
7. Hutfless R., Kazanegra R., Madani M. et al.Utility of B-type natriuretic peptide in predicting postoperative complications and outcomes in patients undergoing heart surgery. J. Am. Coll. Cardiol. 2004; 43 (10): 1873—1879.
8. Roques F., Michel P., Goldstone A. R., Nashef S. A.The logistic EuroSCORE. Eur. Heart J. 2003; 24 (9): 881—882.
9. Eagle K. A, Guyton R. A, Davidoff R. et al.ACC/AHA guidelines for coronary artery bypass graft surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery). American College of Cardiology/American Heart Association. J. Am. Coll. Cardiol. 1999; 34 (4): 1262—1347.
10. Шабалкин Б. В., Трекова H. A., Яворовский А. Г. и соавт.Профилактическое использование внутриаортальной баллонной контрпульсации при операциях аортокоронарного шунтирования. Грудн. и серд.-сосуд. хируругия 2001; 5: 17—19.
11. Tritapepe L., De Santis V., Vitale D. et al.Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. Br. J. Anaesth. 2009; 102 (2): 198—204.
12. Константинов Б. А., Зюляева T. П., Еременко A. A. и соавт.Превентивная внутриаортальная баллонная контрпульсация при хирургической реваскуляризации миокарда. Хирургия 2006; 1: 3—8.
13. Bernard F., Denault A., Babin D. et al.Diastolic dysfunction is predictive of difficult weaning from cardiopulmonary bypass. Anesth. Analg. 2001; 92 (2): 291—298.
14. Dahlstrom U.Can natriuretic peptides be used for the diagnosis of diastolic heart failure? Eur. J. Heart Fail. 2004; 6 (3): 281—287.
15. Шевченко Ю. Л., Попов Л. В., Волкова Н. О., Травин Н. О.Интраопе-рационная чреспищеводная эхокардиография при вмешательствах на сердце. М.: ГЭОТАР-Медиа; 2004. 207.
16. Gheorghiade M., Pang P. S.Are BNP changes during hospitalization for heart failure a reliable surrogate for predicting the effects of therapies on post-discharge mortality? J. Am. Coll.Cardiol. 2009; 53 (25): 2349—2352.
17. Редкобородая А. А.Маркёры воспаления и дисфункции миокарда при внутриаортальной баллонной контрпульсации и искусственном кровообращении: автореф. … канд. мед. наук, М.; 2007. 25.
18. Козлов И. А., Кричевский Л. А., Шумаков Д. В. и соавт.Плазменный уровень неактивной части предшественника В-типа натрийурети-ческого пептида как предиктора функции сердца при операциях с искусственным кровообращением. Анестезиология и реаниматология 2006; 3: 34—38.
19. Арзикулов Т. С., Жбанов И. В.Реваскуляризация миокарда на работающем сердце. Анналы хирургии 2002; 6: 14—18.
Review
For citations:
Moroz V.V., Nikiforov Yu.V., Krichevsky L.A., Aseyev V.M., Guseva O.G., Burzhunova M.G., Rybakov V.Yu. The Significance of the Cardiac Peptide NT-proBNP in the Assessment of Risk for Myocardial Revascularization in Patients with Decreased Left Ventricular Ejection Fraction. General Reanimatology. 2010;6(2):38. (In Russ.) https://doi.org/10.15360/1813-9779-2010-2-38
Views:
1279
Email this article 